靶向肝星状细胞内的内质网蛋白TXNDC5通过抑制非经典TGFβ信号通路减轻肝纤维化
本研究探讨内质网蛋白TXNDC5在肝纤维化中的作用及作为治疗靶点的潜力。人和小鼠纤维化肝脏中TXNDC5显著上调,尤其在纤维化灶内活化的肝星状细胞中;TXNDC5由TGFβ1诱导,通过氧化还原依赖性JNK和STAT3激活促进肝星状细胞活化、增殖、存活及细胞外基质产生。肝星状细胞特异性敲除Txndc5可逆转小鼠已建立的肝纤维化,提示靶向TXNDC5可能成为改善肝纤维化的新型治疗策略。
要点
- TXNDC5在人及小鼠纤维化肝脏中显著上调,尤其位于纤维化灶内活化的肝星状细胞。
- TXNDC5由TGFβ1经内质网应激和ATF6转录调控诱导,对肝星状细胞活化、增殖、存活及细胞外基质产生是必需且充分的。
- TXNDC5通过其PDI活性依赖的氧化还原机制激活JNK和STAT3,肝星状细胞特异性敲除Txndc5可逆转小鼠已建立的肝纤维化。
核心结论
- 内质网蛋白TXNDC5通过氧化还原依赖性肝星状细胞活化、增殖及过度细胞外基质产生促进肝纤维化。
- 靶向TXNDC5可能成为改善肝纤维化的潜在新型治疗策略。
研究设计与样本
- 对人肝硬化肝脏进行组织学和转录组分析。
- 使用Col1a1-GFPTg、Alb-Cre;Rosa26-tdTomato和Tie2-Cre/ERT2;Rosa26-tdTomato小鼠确定肝损伤后TXNDC5诱导的细胞类型。
- 在人肝星状细胞中进行体外研究。
- 生成Col1a2-Cre/ERT2;Txndc5fl/fl(Txndc5cKO)和Alb-Cre;Txndc5fl/fl(Txndc5Hep-cKO)小鼠,分别敲除肝星状细胞和肝细胞中的TXNDC5。
- 采用四氯化碳处理和胆管结扎手术诱导小鼠肝损伤/纤维化,并用组织学、影像学和生化分析量化肝纤维化程度。
主要发现
- TXNDC5在人及小鼠纤维化肝脏中显著上调,尤其在纤维化灶内活化的肝星状细胞中。
- TGFβ1在肝星状细胞中诱导TXNDC5,且TXNDC5对肝星状细胞的活化、增殖、存活及细胞外基质产生是必需且充分的。
- TGFβ1通过增加内质网应激和ATF6介导的转录调控诱导TXNDC5表达。
- TXNDC5通过其PDI活性依赖的氧化还原机制激活肝星状细胞中的JNK和STAT3,促进肝星状细胞活化并使其抵抗凋亡。
- 肝星状细胞特异性敲除Txndc5可逆转小鼠已建立的肝纤维化。
临床怎么用
- 作者认为靶向TXNDC5可能成为改善肝纤维化的潜在新型治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Liver fibrosis (LF) occurs following chronic liver injuries. Currently, there is no effective therapy for LF. Recently, we identified thioredoxin domain containing 5 (TXNDC5), an ER protein disulfide isomerase (PDI), as a critical mediator of cardiac and lung fibrosis. We aimed to determine if TXNDC5 also contributes to LF and its potential as a therapeutic target for LF. DESIGN: Histological and transcriptome analyses on human cirrhotic livers were performed. Col1a1-GFPTg , Alb-Cre;Rosa26-tdTomato and Tie2-Cre/ERT2;Rosa26-tdTomato mice were used to determine the cell type(s) where TXNDC5 was induced following liver injury. In vitro investigations were conducted in human hepatic stellate cells (HSCs). Col1a2-Cre/ERT2;Txndc5fl/fl (Txndc5cKO ) and Alb-Cre;Txndc5fl/fl (Txndc5Hep-cKO ) mice were generated to delete TXNDC5 in HSCs and hepatocytes, respectively. Carbon tetrachloride treatment and bile duct ligation surgery were employed to induce liver injury/fibrosis in mice. The extent of LF was quantified using histological, imaging and biochemical analyses. RESULTS: TXNDC5 was upregulated markedly in human and mouse fibrotic livers, particularly in activated HSC at the fibrotic foci. TXNDC5 was induced by transforming growth factor β1 (TGFβ1) in HSCs and it was both required and sufficient for the activation, proliferation, survival and extracellular matrix production of HSC. Mechanistically, TGFβ1 induces TXNDC5 expression through increased ER stress and ATF6-mediated transcriptional regulation. In addition, TXNDC5 promotes LF by redox-dependent JNK and signal transducer and activator of transcription 3 activation in HSCs through its PDI activity, activating HSCs and making them resistant to apoptosis. HSC-specific deletion of Txndc5 reverted established LF in mice. CONCLUSIONS: ER protein TXNDC5 promotes LF through redox-dependent HSC activation, proliferation and excessive extracellular matrix production. Targeting TXNDC5, therefore, could be a potential novel therapeutic strategy to ameliorate LF.
引用
- Hung CT, Su TH, Chen YT, et al. Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFβ signalling. Gut. 2021. PMID: 34933915. doi:10.1136/gutjnl-2021-325065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。